The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
Joaquin Mateo
No relevant relationships to disclose
Johann Sebastian De Bono
No relevant relationships to disclose
Ramesh K. Ramanathan
Research Funding - Arno Therapeutics
Maryam B. Lustberg
No relevant relationships to disclose
Andrea Zivi
No relevant relationships to disclose
Dawn Basset
No relevant relationships to disclose
Matthew Ng
No relevant relationships to disclose
Anna-Mary Young
No relevant relationships to disclose
Michelle Garrett
Research Funding - Arno Therapeutics
Shaun Decordova
Research Funding - Arno Therapeutics
Florence I. Raynaud
Employment or Leadership Position - The Institute of Cancer Research, United Kingdom
Timothy Anthony Yap
No relevant relationships to disclose
Alexander A. Zukiwski
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Stefan Proniuk
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Charles L. Shapiro
No relevant relationships to disclose